LakeShore Biopharma Co., Ltd (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company focused on vaccines and therapeutic biologics for infectious diseases and cancer, announced that its shareholders voted overwhelmingly in favor of the merger agreement with Oceanpine Skyline Inc. and its subsidiary Oceanpine Merger Sub Inc. at an extraordinary general meeting held on June 19, 2026. The approval marks a significant step toward the company becoming privately held and delisting its shares from public markets.
According to the company's press release, approximately 92.3% of total outstanding ordinary shares were voted, with 86.2% of votes cast supporting the merger. The transaction is based on the Agreement and Plan of Merger dated November 4, 2025, as amended on April 29, 2026. Under the terms, Merger Sub will merge with and into LakeShore Biopharma, with the company surviving as a wholly owned subsidiary of Parent. The merger is expected to close upon satisfaction of customary conditions.
This decision carries significant implications for LakeShore Biopharma and its stakeholders. The company will cease to be a publicly traded entity, with its shares and warrants no longer listed on the OTC Markets. This move may provide the company with greater operational flexibility away from the quarterly earnings pressures and regulatory requirements of public markets, allowing management to focus on long-term strategic goals. For investors, the merger means a change in liquidity and valuation; shares will no longer be traded publicly, and the company will become privately held.
LakeShore Biopharma, previously known as YS Biopharma, has developed a proprietary PIKA® immunomodulating technology platform and a pipeline targeting Rabies, Hepatitis B, Influenza, and other viral infections. The company operates in China, Singapore, and the Philippines. The merger could accelerate its research and development efforts, particularly for its novel vaccines and biologics, by providing access to private capital and reducing public market distractions.
The forward-looking statements in the press release caution that the merger may not occur as planned due to various risks, including financing availability and satisfaction of closing conditions. However, the shareholder vote represents a strong mandate to proceed. The company will work with other parties to complete the merger in due course. For more details, investors can refer to the company's filings with the SEC, as noted in the release.
This development is crucial for understanding the trajectory of LakeShore Biopharma and the broader trend of biopharmaceutical companies opting to go private to navigate market challenges and focus on innovation. The merger highlights the strategic decisions companies face in balancing public market benefits with the demands of long-term research and development.
